ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Grünenthal, Averitas Announce FDA Approval of QUTENZA for Neuropathic Pain
July 29, 2020Grünenthal announced its U.S. subsidiary Averitas Pharma, received U.S. Food and Drug Administration (FDA) approval for QUTENZA® (capsaicin) 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet... -
Averitas Announces sNDA Filing for QUTENZA for Neuropathic Pain
December 20, 2019Averitas Pharma announced the supplemental New Drug Application (sNDA) for QUTENZA for the treatment of neuropathic pain associated with diabetic peripheral neuropathy ... -
Grunenthal establishes commercial footprint in the US
November 19, 2018Averitas Pharma will be commercialising the pain patch Qutenza (8% capsaicin) for Grunenthal in the US.
Pharma Sources Insight January 2025
